On January 8, 2026, Acrivon Therapeutics, Inc. hosted a corporate webcast showcasing ACR-368 and ACR-2316 clinical data updates, which can be viewed on their investor website. This event is significant from an equity investor perspective, indicating ongoing developments in their clinical programs.